Sangamo BioSciences | SGMO - Cash And Equivalent


Sangamo BioSciences reported $38.34M in Cash and Equivalent for its fiscal quarter ending in June of 2025.





Cash And Equivalent Change Date
Alaunos Therapeutics USD 1.94M 941K Sep/2025
Alnylam Pharmaceuticals USD 1.49B 376.56M Sep/2025
Alterity Therapeutics Limited AUD 15.77M 9.56M Jun/2023
Amgen USD 9.13B 316M Dec/2025
Bayer EUR 5.9B 1.34B Sep/2025
BioCryst Pharmaceuticals USD 84.08M 3.95M Sep/2025
Biogen USD 3.01B 854.3M Dec/2025
BioMarin Pharmaceutical USD 1.25B 36.29M Sep/2025
Cipla INR 7.96B 39.9M Sep/2025
Clal Biotechnology ILS 5.73M 1.71M Dec/2023
Compugen USD 7.46M 985K Sep/2025
CSL USD 2.16B 633M Jun/2025
Gilead Sciences USD 7.33B 2.19B Sep/2025
GlaxoSmithKline GBP 3.3B 303M Sep/2025
Grifols EUR 979.78M 334.84M Dec/2024
Ionis Pharmaceuticals USD 2.24B 1.94B Sep/2025
J&J USD 19.71B 1.48B Dec/2025
Karyopharm Therapeutics USD 37.67M 1.05M Sep/2025
Merck USD 18.17B 10.16B Sep/2025
Novartis USD 9.56B 2.9B Sep/2025
Omeros USD 1.9M 2.36M Jun/2025
Pfizer USD 1.34B 295M Sep/2025
Roche Holding CHF 7.55B 579M Jun/2025
Sangamo BioSciences USD 38.34M 13.16M Jun/2025
Sanofi EUR 7.66B 1.25B Dec/2025
Sarepta Therapeutics USD 613.08M 102.48M Sep/2025
Tectonic Therapeutic USD 268.44M 18.94M Sep/2025
Ultragenyx Pharmaceutical USD 202.51M 36.4M Sep/2025
Vertex Pharmaceuticals USD 6.29B 95.8M Sep/2025